17.2 Syncope Evaluation & Status Epilepticus

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

17.2 Syncope Evaluation & Status Epilepticus

Key Takeaways Explain This Topic AI

Transient loss of consciousness (TLOC) must be systematically differentiated between syncope (abrupt onset, brief duration, and spontaneous complete neurological recovery), epileptic seizures (prolonged postictal confusion >15–30 min, lateral tongue biting [>99% specificity], and synchronous motor convulsions), and psychogenic non-epileptic seizures (PNES; active eyelid resistance to opening and asynchronous out-of-phase motor thrashing).

Clinical prediction tools, specifically the San Francisco Syncope Rule (CHESS criteria: Congestive heart failure, Hematocrit <30%, ECG abnormal, Shortness of breath, Systolic BP <90 mm Hg), identify high-risk patients who require telemetry admission and comprehensive cardiovascular evaluation.

High-risk cardiac syncope is distinguished by sudden unheralded onset without prodrome, syncope occurring during physical exertion or in the supine position, known structural heart disease (aortic stenosis, hypertrophic cardiomyopathy), or ECG findings of channelopathies (Brugada pattern, long QTc, pre-excitation, high-grade AV block).

Status epilepticus (SE) is an operational medical emergency defined as continuous seizure activity lasting ≥5 minutes, or ≥2 discrete seizures between which there is incomplete recovery of consciousness; therapeutic delay beyond 5 minutes triggers progressive GABA-A receptor internalization and NMDA receptor upregulation, producing pharmacoresistance.

Pharmacological escalation in status epilepticus follows a strict phased protocol: Phase 2 (5–20 min) requires first-line benzodiazepines (IV lorazepam 0.1 mg/kg [4 mg] or IM midazolam 10 mg); Phase 3 (20–40 min) requires second-line non-sedating AEDs (IV levetiracetam 60 mg/kg [max 4500 mg], IV fosphenytoin 20 mg PE/kg [max 1500 mg PE], or IV valproate sodium 40 mg/kg [max 3000 mg]); Phase 4 (>40 min, refractory SE) mandates endotracheal intubation, continuous anesthetic infusions (propofol, midazolam, or ketamine), and continuous video-EEG monitoring.

Last updated: September 2026

Differential Diagnosis of Transient Loss of Consciousness (TLOC)

Transient Loss of Consciousness (TLOC) is defined as a state of real or apparent loss of consciousness characterized by amnesia for the period of the event, abnormal motor control, loss of responsiveness, and brief duration. Clinical differentiation among Syncope , Generalized Epileptic Seizures , and Psychogenic Non-Epileptic Seizures (PNES) is paramount, as misdiagnosis leads to unnecessary anti-seizure drug toxicity, driving restrictions, or missed fatal cardiac arrhythmias.

Comprehensive Clinical Discriminators of TLOC

Clinical Characteristic Syncope (Vasovagal or Cardiac) Generalized Tonic-Clonic Seizure Psychogenic Non-Epileptic Seizures (PNES)

Underlying Mechanism Transient global cerebral hypoperfusion Paroxysmal, hypersynchronous cortical neuronal firing Conversion / functional neurological symptom disorder

Onset / Warning Prodrome • Vasovagal : Lightheadedness, warmth, diaphoresis, nausea, pallor, tunnel vision; • Cardiac : Abrupt, instantaneous collapse without any warning Stereotyped sensory or visceral aura (epigastric rising sensation, metallic taste, déjà vu, focal twitching) Waxing and waning emotional distress, hyperventilation, closed eyes, prolonged theatrical warning

Duration of Unconsciousness Extremely brief: usually <30 to 60 seconds Intermediate: typically 1 to 2 minutes Prolonged: often >5 to 20 minutes ; episodic waxing and waning

Motor Manifestations Atonic flaccidity; brief (<15s), asynchronous, non-rhythmic myoclonic twitches may occur after the fall ( convulsive syncope ) Sustained, rhythmic, synchronous bilateral tonic extension followed by clonic jerking (60–90s) Out-of-phase asynchronous thrashing of limbs, pelvic thrusting, side-to-side "no-no" head shaking

Tongue Laceration Absent, or laceration confined strictly to the anterior tip of the tongue Laceration of the LATERAL BORDER of the tongue (highly specific, >99%) Absent, or superficial lip/cheek biting

Eyelid State & Resistance Eyes open, blank stare or slight upward rolling Eyes open, fixed, prominent upward or lateral conjugate deviation Tightly closed eyes with active resistance to passive opening ; bells phenomenon; normal pupillary light reflexes

Postictal State Immediate lucidity : Fully oriented within <1 to 2 minutes; no retrograde amnesia Prolonged confusion, somnolence, headache, muscle soreness lasting >15 to 30 minutes ; Todd's paresis Rapid recovery without confusion, or dramatic emotional weeping; normal orientation immediately after event

Serum Laboratory Markers Serum prolactin normal; venous lactate normal or transiently elevated <2.5 mmol/L Markedly elevated venous lactate (>5–10 mmol/L, clearing within 60 min); elevated serum prolactin (drawn within 20 min) Normal venous lactate and normal serum prolactin

Clinical Discriminator Pearls

Lateral Tongue Biting : Spasm of the lateral pterygoid and masseter muscles during generalized epileptic seizure forces the lateral margin of the tongue between the molars, producing deep lateral lacerations. Conversely, tongue injuries in syncope are secondary to blunt trauma against the incisors during a fall, producing abrasions confined to the tip of the tongue.

Convulsive Syncope : When cerebral perfusion ceases for >5 to 10 seconds, brief cortical and subcortical ischemic release occurs, producing non-rhythmic, asynchronous myoclonic jerking. Clinicians frequently misdiagnose convulsive syncope as epilepsy; the absence of lateral tongue biting, lack of a prolonged postictal state, and immediate lucidity confirm syncope.

Urinary Incontinence : Can occur in both syncope and epileptic seizures due to sudden loss of central autonomic inhibition over the bladder detrusor muscle. It possesses zero discriminatory value .

Clinical Prediction Tools for Syncope: San Francisco Rule & Canadian Score

Syncope accounts for 1% to 3% of all emergency department visits. The clinical mandate is to distinguish benign reflex syncope from life-threatening cardiovascular etiologies carrying high 30-day risks of sudden cardiac death.

The San Francisco Syncope Rule (SFSR)

The SFSR was developed to identify patients at high risk for serious 30-day outcomes (death, acute myocardial infarction, life-threatening arrhythmia, pulmonary embolism, stroke, subarachnoid hemorrhage, or severe hemorrhage requiring transfusion ≥ 2 units). Patients meeting ANY ONE OF THE 5 "CHESS" CRITERIA are classified as HIGH RISK and require admission with continuous telemetry monitoring: THE SAN FRANCISCO SYNCOPE RULE: "CHESS"

• ┌───┬────────────────────────────────────────────────────────────────────┐
• │ C │ History of CONGESTIVE HEART FAILURE │
• │ │ • Documented ischemic or non-ischemic cardiomyopathy │
• │ │ • Clinical signs of active decompensation (rales, JVD, S3) │
• ├───┼────────────────────────────────────────────────────────────────────┤
• │ H │ HEMATOCRIT <30% (or Hemoglobin <10 g/dL) │
• │ │ • Suggests occult gastrointestinal bleeding or major hemorrhage │
• ├───┼────────────────────────────────────────────────────────────────────┤
• │ E │ ABNORMAL ECG │
• │ │ • Any non-sinus rhythm (atrial fibrillation, flutter, VT, SVT) │
• │ │ • Conduction delay: QRS >120 ms, LBBB, bifascicular block │
• │ │ • Pathological Q waves, ischemic ST-segment/T-wave changes │
• │ │ • Long QTc interval (>450 ms in men, >460 ms in women) │
• │ │ • Brugada pattern, pre-excitation (short PR, delta wave) │
• ├───┼────────────────────────────────────────────────────────────────────┤
• │ S │ SHORTNESS OF BREATH │
• │ │ • Dyspnea pointing toward pulmonary embolism, acute MI, or heart │
• │ │ failure exacerbation │
• ├───┼────────────────────────────────────────────────────────────────────┤
• │ S │ SYSTOLIC BLOOD PRESSURE <90 mm Hg │
• │ │ • Triage hypotension reflecting cardiogenic, hypovolemic, or │
• │ │ distributive shock │
• └───┴────────────────────────────────────────────────────────────────────┘
• The Canadian Syncope Risk Score (CSRS)

The CSRS is an internationally validated, 9-variable clinical decision model that stratifies 30-day serious adverse cardiovascular outcomes from Very Low (-3 to -2 points, 0.4% risk) to Very High (≥ 6 points, >80% risk):

Clinical evaluation: Predisposition to vasovagal syncope (-1), history of heart disease (+1), SBP <90 or >180 mm Hg (+2).

Investigations: Elevated cardiac troponin I/T (+2), abnormal ECG (+1).

ED impression: Vasovagal syncope (-2), cardiac syncope (+2).

• Etiological Spectrum & Risk Stratification of Syncope
• 1. Cardiac Syncope (High-Risk: Predicts 30-Day Sudden Death)

Cardiac syncope results from an acute reduction in cardiac output due to either electrical arrhythmias or mechanical/structural obstruction. Untreated 1-year mortality approaches 20% to 30% .

A. Arrhythmic Etiologies

Ventricular Tachycardia (VT) : Most common cause of cardiac syncope in patients with prior myocardial infarction, ischemic cardiomyopathy, or depressed left ventricular ejection fraction (LVEF <35%).

High-Grade Atrioventricular (AV) Conduction Blocks : Mobitz type II second-degree AV block and third-degree complete AV block (producing abrupt ventricular standstill or profound bradycardia; Stokes-Adams attacks).

Sinus Node Dysfunction (Sick Sinus Syndrome) : Severe sinus bradycardia, sinoatrial exit block, or prolonged sinus pauses >3 seconds (especially during tachy-brady syndrome upon termination of rapid atrial fibrillation).

Inherited Cardiac Channelopathies :

Brugada Syndrome : Autosomal dominant mutation in cardiac sodium channels (SCN5A). Characteristic ECG: coved ST-segment elevation ≥ 2 mm followed by a negative T wave across leads V1–V2 (Type 1 Brugada pattern) . Predisposes to polymorphic VT and ventricular fibrillation, particularly during febrile illnesses or sleep. Requires implantable cardioverter-defibrillator (ICD).

Congenital Long QT Syndrome (LQTS) : Genetic mutations in potassium or sodium channels prolonging ventricular repolarization (QTc >460 ms in males, >480 ms in females; >500 ms carries extreme risk of Torsades de Pointes ). Subtypes: LQT1 (triggered by exercise/swimming), LQT2 (triggered by loud auditory stimuli/alarm clocks), LQT3 (triggered by sleep/rest).

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) : Fibrofatty replacement of RV myocardium. ECG features: T-wave inversions in V1–V3 and an epsilon wave (notched deflection at the terminal end of the QRS complex).

Wolff-Parkinson-White (WPW) Syndrome : Short PR interval (<120 ms), widened QRS with a slur ( delta wave ); syncope reflects rapid pre-excited atrial fibrillation traversing the accessory pathway.

B. Structural & Mechanical Obstructive Etiologies

Severe Aortic Stenosis : Classic triad of exertional syncope, angina, and dyspnea . In severe AS (aortic valve area <1.0 cm², mean gradient >40 mm Hg), exercise-induced skeletal muscle vasodilation cannot be matched by an increase in cardiac output across the fixed, calcified orifice, precipitating profound cerebral hypoperfusion. Physical findings: Harsh, crescendo-decrescendo late-peaking systolic ejection murmur radiating to the carotids with pulsus parvus et tardus (weak, delayed carotid upstroke).

Hypertrophic Cardiomyopathy (HCM) : Asymmetric septal hypertrophy causing dynamic left ventricular outflow tract (LVOT) obstruction and systolic anterior motion (SAM) of the anterior mitral valve leaflet. Physical findings: Harsh systolic ejection murmur at the left lower sternal border that intensifies with Valsalva strain or standing (decreased preload worsens obstruction) and softens with squatting (increased preload opens outflow tract).

Massive Pulmonary Embolism : Physical saddle obstruction of the main pulmonary artery trunk causing acute RV collapse and left ventricular underfilling.

Acute Aortic Dissection (Type A) : Retrograde extension causing acute hemopericardium and cardiac tamponade.

Atrial Myxoma : Pedunculated intracavitary benign cardiac tumor (most commonly left atrium) that intermittently prolapses into and obstructs the mitral valve orifice when upright.

Red Flags Demanding Immediate Admission for Cardiac Syncope

Syncope occurring during physical exertion or active exercise (strongly correlates with severe AS, HCM, or anomalous coronary arteries).

Syncope occurring in the supine position or while lying flat (rules out orthostatic and vasovagal etiologies; highly specific for an arrhythmia).

Absence of any prodromal warning symptoms (sudden unheralded drop attack).

Syncope preceded immediately by rapid, fluttering palpitations or angina .

Family history of unexplained sudden cardiac death, drowning, or fatal single-vehicle accidents at age <40 years .

Known severe underlying structural heart disease (prior MI, severe congestive heart failure, LVEF <35%).

2. Orthostatic Syncope

Occurs when gravitational pooling of blood within the venous capacitance vessels of the lower extremities and splanchnic circulation upon standing impairs venous return, resulting in a precipitous drop in stroke volume and arterial pressure.

Diagnostic Criteria for Orthostatic Hypotension : A sustained reduction in systolic blood pressure of ≥ 20 mm Hg OR a reduction in diastolic blood pressure of ≥ 10 mm Hg within 3 minutes of standing from a supine position (or during head-up tilt testing).

Clinical Categories :

Intravascular Volume Depletion : Dehydration, persistent vomiting, diarrhea, acute hemorrhage, excessive diaphoresis, or over-diuresis.

Medication-Induced (Most Common) : Antihypertensives (diuretics, ACE inhibitors, beta-blockers), alpha-1 adrenergic antagonists (tamsulosin, doxazosin, prazosin) , vasodilators (nitrates, hydralazine), PDE-5 inhibitors (sildenafil), tricyclic antidepressants, and phenothiazines.

Neurogenic Orthostatic Hypotension (Autonomic Failure) : Failure of baroreceptor-mediated vasoconstriction. Observed in primary neurodegenerative disorders ( Parkinson's disease, Multiple System Atrophy [Shy-Drager syndrome], Pure Autonomic Failure ) and secondary autonomic neuropathies ( Diabetic autonomic neuropathy, amyloidosis, Guillain-Barré syndrome ). Key sign: Absence of compensatory reflex tachycardia upon standing (heart rate increases by <10 bpm despite marked hypotension).

3. Neurally-Mediated (Reflex) Syncope (Benign)

Reflex syncope is characterized by an inappropriate, paradoxical neurocardiovascular reflex causing systemic vasodilation (vasodepressor response) and/or bradycardia (cardioinhibitory response).

Vasovagal Syncope (Common Neurocardiogenic Faint) :

Triggers: Intense emotional distress, fear, severe pain, sight of blood, medical instrumentation (venipuncture), or prolonged motionless standing in crowded, overheated rooms.

Pathophysiology: Sympathetic surge triggers vigorous ventricular contraction against an underfilled chamber, activating ventricular mechanoreceptors ( Bezold-Jarisch reflex ). This paradoxically triggers massive vagal efferent discharge (causing sinus bradycardia or sinus arrest) and sympathetic withdrawal (causing peripheral arteriolar and venous dilation).

Classic Prodrome: Sweating (diaphoresis), warmth, pallor, yawning, nausea, abdominal discomfort, visual blurring, and lightheadedness lasting seconds to minutes before collapse.

Situational Syncope :

Micturition Syncope : Occurs during or immediately after nocturnal urination in men standing to void; rapid relief of bladder distension triggers a vagal surge, compounded by nighttime orthostasis and warm bed-to-bathroom vasodilation.

Defecation Syncope : Triggered by prolonged Valsalva straining during difficult bowel movements.

Cough (Tussive) Syncope : Paroxysms of coughing markedly increase intrathoracic pressure, impeding venous return to the right heart.

Swallow Syncope : Deglutition triggers vagal esophageal mechanoreceptors.

Carotid Sinus Hypersensitivity :

Exaggerated baroreceptor reflex triggered by mechanical stimulation of the carotid bulb (turning neck, looking upward, shaving, wearing tight collars).

Diagnostic Confirmation: Carotid sinus massage performed under continuous ECG monitoring (after auscultating to exclude carotid bruits and history of TIA/stroke). Positive response: ventricular pause ≥ 3 seconds (cardioinhibitory) or a drop in SBP ≥ 50 mm Hg without significant bradycardia (vasodepressor) .

Status Epilepticus (SE): Operational Definition & Pathophysiology

Status epilepticus is a medical emergency characterized by the failure of endogenous mechanisms responsible for terminating seizures, or the initiation of mechanisms that lead to abnormally prolonged seizure activity.

Operational Guideline Definition (Neurocritical Care Society & AES)

Historical definitions required 30 minutes of continuous seizure activity. Current neurocritical guidelines establish a dual-time-point operational framework based on when emergency pharmacotherapy must begin (t1) and when long-term irreversible neuronal injury starts (t2): STATUS EPILEPTICUS DUAL-TIME-POINT DEFINITION

• t1 = 5 MINUTES t2 = 30 MINUTES
• ───────────┼──────────────────────────────────────────────────┼───────────►
• │ │
• ▼ ▼

OPERATIONAL THRESHOLD: NEURONAL INJURY THRESHOLD:

• Seizure lasting ≥5 min, OR • Irreversible neuronal necrosis
• ≥2 seizures without complete and cell death actively ensue
• recovery of consciousness • Alteration of neuronal networks
• MANDATES IMMEDIATE FIRST-LINE • Severe systemic complications
• EMERGENCY PHARMACOTHERAPY (acidosis, rhabdomyolysis)

Time Point 1 (t1 = 5 minutes) : A generalized convulsive seizure lasting ≥ 5 minutes rarely terminates spontaneously and requires immediate emergency pharmacotherapy . (For focal status epilepticus with impaired awareness, t1 = 10 minutes).

Time Point 2 (t2 = 30 minutes) : Duration beyond which irreversible neuronal injury, excitotoxic cell death, and permanent network reorganization occur. (For focal status epilepticus, t2 = 60 minutes).

Cellular Pathophysiology & Receptor Trafficking

Within minutes of continuous seizure activity, dramatic receptor trafficking alters neuronal membrane responsiveness:

GABA-A Receptor Internalization : Synaptic GABA-A receptors undergo clathrin-mediated endocytosis into intracellular endosomes, reducing the number of functional inhibitory GABA-A receptors on the postsynaptic membrane. Consequently, the brain becomes progressively refractory to benzodiazepines (which require functional GABA-A receptors to exert their inhibitory effect).

Glutamate Receptor Mobilization : Concurrently, excitatory NMDA and AMPA glutamate receptors are translocated from intracellular stores to the postsynaptic membrane , upregulating excitatory transmission.

Excitotoxicity & Systemic Collapse : Continuous glutamatergic stimulation causes massive intracellular calcium influx, activating proteases, lipases, and apoptotic cascades, destroying hippocampal CA1/CA3 pyramidal neurons and cortical layers. Systemically, unremitting muscle contraction triggers severe lactic acidosis (pH frequently <7.0), hyperthermia (>40°C), rhabdomyolysis, hyperkalemia, acute tubular necrosis, and cardiac arrhythmias.

Stepwise Pharmacological Management of Status Epilepticus

Management must proceed rapidly through four sequential, time-delineated phases. Underdosing of first-line benzodiazepines is the single most prevalent mistake in clinical practice and leads directly to treatment failure. STATUS EPILEPTICUS STEPWISE PHARMACOTHERAPY

• ┌────────────────────────────────────────────────────────────────────────┐
• │ PHASE 1: STABILIZATION & EVALUATION (0 TO 5 MINUTES) │
• │ • Airway, Breathing, Circulation; high-flow O2 via non-rebreather │
• │ • Continuous cardiac telemetry, pulse oximetry, blood pressure │
• │ • STAT Point-of-Care Capillary Glucose: If <70 mg/dL, give D50W 50 mL │
• │ • If alcohol use / malnutrition suspected: IV THIAMINE 100–500 mg │
• │ BEFORE Dextrose │
• │ • Establish two large-bore peripheral IV lines │
• │ • STAT Labs: CBC, CMP, Mg, Phos, Ca, Tox screen, AED levels, ABG/VBG │
• └───────────────────────────────────┬────────────────────────────────────┘
• │ Seizure continues ≥5 minutes
• ▼
• ┌────────────────────────────────────────────────────────────────────────┐
• │ PHASE 2: EMERGENT INITIAL THERAPY (5 TO 20 MINUTES) │
• │ FIRST-LINE BENZODIAZEPINES (FULL WEIGHT-BASED DOSES): │
• │ • IF IV ACCESS AVAILABLE: │
• │ - IV LORAZEPAM: 0.1 mg/kg IV (typical dose 4 mg IV push over 2 min); │
• │ may repeat once after 5–10 min if seizure persists │
• │ • IF NO IV ACCESS AVAILABLE (IM IS FASTER THAN IV DELAY - RAMPART): │
• │ - IM MIDAZOLAM: 10 mg IM single dose (>40 kg) (5 mg IM if 13–40 kg) │
• │ • ALTERNATIVE IF NO IV/IM: │
• │ - RECTAL DIAZEPAM GEL (Diastat): 0.2 mg/kg per rectum (max 20 mg) │
• │ - Intranasal Midazolam: 0.2 mg/kg (max 10 mg) │
• └───────────────────────────────────┬────────────────────────────────────┘
• │ Seizure continues ≥20 minutes
• ▼
• ┌────────────────────────────────────────────────────────────────────────┐
• │ PHASE 3: URGENT CONTROL THERAPY (20 TO 40 MINUTES) │
• │ SECOND-LINE IV ANTIEPILEPTIC DRUGS (ESETT TRIAL: EQUAL EFFICACY ~50%): │
• │ • IV LEVETIRACETAM (Keppra): 60 mg/kg IV over 10 min (MAX 4500 mg) │
• │ - Minimal cardiac/hemodynamic side effects; no drug interactions │
• │ • IV FOSPHENYTOIN (Cerebyx): 20 mg PE/kg IV (MAX 1500 mg PE) @ 150 mg/m│
• │ - Water-soluble prodrug; avoids purple-glove tissue necrosis │
• │ - Requires continuous ECG monitoring (can cause bradycardia/hypotn) │
• │ • IV SODIUM VALPROATE: 40 mg/kg IV over 10 min (MAX 3000 mg) │
• │ - Contraindicated in acute liver disease, pregnancy, urea cycle d/o │
• └───────────────────────────────────┬────────────────────────────────────┘
• │ Seizure continues ≥40 minutes
• ▼
• ┌────────────────────────────────────────────────────────────────────────┐
• │ PHASE 4: REFRACTORY STATUS EPILEPTICUS (RSE, >40 MINUTES) │
• │ ICU ADMISSION, ENDOTRACHEAL INTUBATION & GENERAL ANESTHETIC INFUSION: │
• │ • Endotracheal intubation with rapid-sequence induction (avoid succin- │
• │ ylcholine if hyperkalemic/rhabdomyolysis; use rocuronium 1.2 mg/kg) │
• │ • CONTINUOUS VIDEO-EEG MONITORING (MANDATORY): Rule out non-convulsive │
• │ status epilepticus (electromechanical decoupling) │
• │ • TITRATABLE ANESTHETIC CONTINUOUS INFUSIONS: │
• │ - PROPOFOL: 1–2 mg/kg IV bolus, then 2–10 mg/kg/hour continuous │
• │ infusion (watch for Propofol Infusion Syndrome [PRIS]) │
• │ - MIDAZOLAM: 0.2 mg/kg IV bolus, then 0.05–2.0 mg/kg/hour infusion │
• │ - KETAMINE: 1–2 mg/kg IV bolus, then infusion (blocks upregulated │
• │ NMDA receptors; excellent hemodynamic stability) │
• │ • Titrate infusions to electrographic burst suppression (10–15s pause) │
• └────────────────────────────────────────────────────────────────────────┘
• Critical Clinical Pearls in Status Management

The RAMPART Trial : Demonstrated that prehospital intramuscular midazolam (10 mg IM) is non-inferior (and resulted in a higher rate of seizure cessation prior to ED arrival: 73% vs 63%) compared to intravenous lorazepam (4 mg IV). Establishing IV access in a violently seizing patient causes substantial treatment delays; IM midazolam should be administered immediately if an IV line is not already in place.

The ESETT Trial : Demonstrated that in status epilepticus refractory to benzodiazepines, levetiracetam (60 mg/kg), fosphenytoin (20 mg PE/kg), and valproate sodium (40 mg/kg) had statistically indistinguishable rates of seizure cessation (~47% each) and identical safety profiles. Levetiracetam is often preferred in clinical practice due to rapid infusion time, lack of cardiotoxicity, and zero hepatic cytochrome P450 interactions.

Non-Convulsive Status Epilepticus (Electromechanical Decoupling) : After 30 to 45 minutes of convulsive status epilepticus, overt rhythmic motor jerking frequently diminishes or ceases completely due to neuromuscular exhaustion. However, continuous, damaging electrographic seizure activity persists in the brain ( Non-Convulsive Status Epilepticus ). Continuous EEG (cEEG) monitoring is mandatory in any patient who does not regain consciousness within 20 minutes of convulsive seizure termination .

Loading diagram... Comprehensive Clinical Flowchart: TLOC Evaluation & Status Epilepticus Protocol